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INTRODUCTION
Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF)
has been increasingly recognized. Revised Japanese criteria for
AE of IPF (AE-IPF) have been available in 2004 in Japan (1) and
the international consensus criteria were published in 2007 (2).
Recently, AE has also been shown to develop in interstitial pneu-
monias (IPs) other than IPF, such as idiopathic nonspecific inter-
stitial pneumonia (NSIP) and connective tissue disease (CTD)
associated interstitial pneumonia (CTD-IP) (3-7). Park et al. (6)
have described that AE developed in four of 93 patients with CTD-
IP and that all patients who experienced AE died. Suda et al. (7)
reported that six of 83 CTD-IP patients developed AE and that five
of six (83.3%) expired. These data suggest that AE can also occur
in CTD-IP, and this condition is closely similar to that of IPF with
poor prognosis. However, the cumulative reported number of CTD-
IP patients with AE is small, and its clinical characteristics remain
to be fully determined. In the present study, we investigated the
incidence, clinical features and outcome of AE of CTD-IP in our
department.
PATIENTS AND METHODS
Patients
We retrospectively reviewed 3432 patients (all Japanese) who
admitted to our department from January 2011 to December 2015.
There were 312 patients diagnosed with CTD according to the
established criteria (8-13). Among them, 155 had accompanied
with IP that was diagnosed by radiological pattern on high-reso-
lution computed tomography (HRCT) according to the ATS/ERS/
JRS/ALAT statement (14). The surgical lung biopsy was not done
in any patients. Fifty -six patients developed acute deterioration of
respiratory condition, and 10 were diagnosed as AE of IP (AE-IP)
according to the criteria described below. The statement on con-
sent to participate in this study was obtained from patients by writ-
ten informed consent forms, if applicable, or by the disclosure of
information for participation. The study was performed in accor-
dance with the Declaration of Helsinki and the study protocol was
approved by the Institutional Review Board of Tokushima Uni-
versity Hospital.
Definition of AE-IP
AE-IP was defined based on the criteria for AE-IPF proposed
by the Japanese guidelines (1) or the IPF Clinical Research Net-
work (2), with a slight modification for the adaptation to CTD-IP
(7, 15) : 1) previous or concurrent diagnosis of underlying fibrotic
IP ; 2) unexplained worsening or development of dyspnea within
30 days ; 3) HRCT scan with new bilateral ground-glass opacities
and/or consolidation superimposed on a background reticular or
honeycombing pattern ; 4) no evidence of pulmonary infection by
negative respiratory culture and negative blood tests for potentially
infectious pathogens (e.g. Cytomegalovirus, Pneumocystis jirovecii) ;
and 5) exclusion of left heart failure, pulmonary embolism and
alternative causes for acute lung injury. If aforementioned deterio-
ration and progression takes more than 30 days, we defined it as
‘IP progression’.
Statistical analyses
Survival was estimated using the Kaplan-Meier method, and the
difference was assessed via the Log-rank test. Cox proportional haz-
ards regression analysis was used to identify significant variables
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predicting survival status. Variables selected via univariate test
were evaluated using a multivariate Cox regression analysis. p
0.05 was deemed statistically significant. All statistical analyses
were performed with EZR (Saitama Medical Centre, Jichi Medical
University ; Kanda, 2012, version 1.32), which is a graphical user
interface for R (The R Foundation for Statistical Computing, ver-
sion 3.25) (16).
RESULTS
The incidence of AE in CTD-IP patients
There were 312 CTD patients who fulfilled the eligibility criteria
and 155 (49.7%) had IP among them in this study. Of all CTD-IP
patients, 56 (36.1%) were hospitalized due to acute deterioration
of respiratory condition. The hospitalization cause was AE in ten
patients (6.5%). Other causes of acute deterioration were respira-
tory infection (24 cases), IP progression (5 cases), pulmonary
hypertension (PH) (4 cases), drug- induced pneumonia (4 cases),
alveolar hemorrhage (3 cases), pulmonary embolism (2 cases),
sepsis (2 cases), pneumothorax (1 case) and aortic dissection
(1 case) (Figure 1). No cases experienced the relapse of AE.
Clinical features of patients with AE of CTD-IP
Table 1 shows the clinical characteristics of 10 patients with AE
of CTD-IP. There were three female (30%) and the median age at
the onset of AE was 73 years. The median period was 958 days from
the diagnosis of IP to AE occurrence. Six (60%) were ex-smokers
with 3.5-5 pack-years of smoking history. Patients with rheuma-
toid arthritis (RA) (6 cases), systemic lupus erythematosus (SLE)
(1 case) and Sjögren syndrome (SS) (1 case) had UIP pattern in
HRCT. Two polymyositis (PM)/dermatomyositis (DM) patients
had NSIP pattern in HRCT. All except one SS patient were treated
with corticosteroid. Patients with RA (4 cases) were treated with
the combination of corticosteroid and other drugs ; methotrexate,
cyclosporine A (CsA), etanercept, salazosulfapyridine, bucillamine.
One SLE patient was accompanied with PH and treated with silde-
nafil. The mean serum levels of IP biomarkers, LDH and KL-6,
were elevated. The mean value of the partial pressure of arterial
oxygen/fraction of inspired oxygen ratio was 149.4.
Treatment and outcome of AE in CTD-IP patients
The treatment and outcome of AE of CTD-IP is summarized in
Table 2. All patients were treated with broad-spectrum antimicro-
bial agents and high dose corticosteroid. Six received steroid pulse
therapy, intravenous bolus 1000 mg methylprednisolone (mPSL),
and two received half pulse (500 mg mPSL) therapy once daily for
3 days, then followed by 1 mg/kg/day and 0.5-0.7 mg/kg/day of
prednisolone (PSL) in 5 and 3 patients, respectively. The dose of
PSL was increased to 1 mg/kg/day without pulse therapy in two
patients. The response to initial corticosteroid therapy was evalu-
ated within one week and immunosuppressant was added in two
patients with poor response to corticosteroid. The indicated im-
munosuppressant was intravenously administered cyclophos-
phamide (IVCY) and tacrolimus (TAC) in one each patient. Two
patients were increased the dose of CsA. Only two patients were
managed with a ventilator during their clinical course. Median
survival time after the onset of AE was 169 days in all 10 patients
(Figure 2A). The median survival time after the onset of AE was
significantly longer in patients treated with corticosteroid only com-
Figure 1. Trial profile.
CTD ; connective tissue disease, IP ; interstitial pneumonia, HRCT ; high-resolution computed tomography, RA ; rheumatoid arthritis, PM ; poly-
myositis, DM ; dermatomyositis, SLE ; systemic lupus erythematosus, SS ; Sjögren syndrome, UIP ; usual interstitial pneumonia, NSIP ; nonspecific
interstitial pneumonia
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Table 1. Clinical characteristics of patients with AE of CTD-IP at the
onset of AE
Number of patients
or values (N=10)
Sex male/female 7/3
Age (years)a 73 (61-83)
Smoking status current/ex-smoker/never 0/6/4
Period from diagnosis of IP to AE occurrence
(days)a 958 (415-2714)
Underlying connective tissue disease
RA 6
PM/DM 2
SLE 1
SS 1
Radiological pattern
UIP 8
NSIP 2
Treatment for CTD and IP
PSL only 3
PSL and other drugsb 6
No drugs 1
Long- term oxygen therapy 3
Laboratory data
LDH (IU/mL)c 312.370.4
KL-6 (U/mL)c 955.7455.4
PaO2/ FIO2 Ratio (N=7)c 149.4100.5
a ; median (range), b ; other drugs : methotrexate, cyclosporine A, etan-
ercept, salazosulfapyridine, bucillamine, sildenafil. c ; meanSD
AE ; acute exacerbation, CTD-IP ; connective tissue disease associated
interstitial pneumonia, RA ; rheumatoid arthritis, PM ; polymyositis, DM ;
dermatomyositis, SLE ; systemic lupus erythematosus, SS ; Sjögren syn-
drome, UIP ; usual interstitial pneumonia, NSIP ; nonspecific interstitial
pneumonia, CTD ; connective tissue disease, IP ; interstitial pneumonia,
PSL ; prednisolone, LDH ; lactate dehydrogenase, KL-6 ; Krebs von den
Lungen-6
Table 2. Treatment and outcome of AE in CTD-IP patients
Number of patients
or values (N=10)
Treatment
mPSL pulse therapy
1 g/500 mg/none 6/2/2
PSL
1 mg/kg/day/0.5 -0.7 mg/kg/day 7/3
Immunosuppresants
IVCY/TAC 1/1
Oxygen therapy
Ventilation/NPPV/reservoir mask/nasal
cannula 2/1/2/5
Outcome
Died of AE 1 (10%)
Survive from AE 9 (90%)
Survival after AE (days)a 169 (15-1391)
Survival rate
30 days 90% (9/10)
90 days 70% (7/10)
Causes of death
AE 1 (10%)
Respiratory infection 2 (20%)
Othersb 4 (40%)
a ; median (range), b ; Others : lung cancer, sudden death of unknown
cause, aortic dissection, suffocation due to aspiration
AE ; acute exacerbation, CTD-IP ; connective tissue disease associated
interstitial pneumonia, mPSL ; methylprednisolone, PSL ; prednisolone,
IVCY ; intravenous cyclophosphamide, CsA ; cyclosporineA, TAC ;
tacrolimus, NPPV ; noninvasive positive pressure ventilation
Figure 2. Kaplan-Meier estimates of the survival after the onset of AE of CTD-IP in all patients (A), and in patients with poor response to
corticosteroid (straight line) or patients treated with corticosteroid only (dotted line) for the treatment of AE (B). P value was examined by the Log-
rank test.
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pared with those with poor response to corticosteroid (805 days
and 45 days, respectively) (p0.05 ; Figure 2B). Three patients
died within 90 days ; one patients, RA with UIP pattern, died of AE
within 30 days, and the other two patients died of respiratory in-
fection within 90 days. During follow-up periods, one each patient
died of lung cancer, sudden death of unknown cause, aortic dis-
section, suffocation due to aspiration.
DISCUSSION
AE of interstitial lung disease (ILD) is well known to be a fatal
event during its clinical course. Contrary to AE-IPF, the signifi-
cance of AE of CTD-IP has not been so widely recognized, and its
clinical feature is not fully elucidated. In this study, we retrospec-
tively investigated the clinical features and outcome of AE of CTD-
IP. The number of CTD-IP patients was 155 ; 36.1% of all hospital-
ized CTD patients. Ten patients of CTD-IP (6.5%) were hospitalized
due to AE, and the mortality of AE in patients experienced AE of
CTD-IP was 10% (1/10). Median survival time after the onset of AE
was 169 days in all 10 patients.
The incidence of IP associated with CTD is reported to be varied
depending on the underlying CTD. In this study, it comprehen-
sively was 36.1% and relatively higher, because the subject of this
study was only hospitalized patients, especially hospitalized due to
deterioration of respiratory condition. Generally, there are more
female patients than male patients in CTD, but the ratio of male
patients was relatively higher in our study, which is consistent with
previous reports (6, 7, 15, 17). In RA-IP, Restrepo et al. (18) re-
ported that 21% of RA patients was male, but 49% of RA-IP patients
was male, and also that 72% of RA-IP patients had a smoking his-
tory. These mean that there are more male patients in CTD with
IP patients. Smoking may relate to CTD-IP, similar to IPF.
The incidence of AE in IP remains mostly unknown. Recently,
several studies reported that the 1-year incidence of AE was 14.2%
in IPF (19), 4.2% in NSIP (6), and 1.25-3.3% in CTD-IP (6, 7). The
incidence of AE in CTD-IP seems to be lower than that in IPF. Suda
et al. (7) revealed an overall incidence of 7.2% in CTD-IP during
follow-up periods, which was comparable with our findings in this
study. The reported mortality of AE was above 70% in IPF (15, 20,
21), 34% in NSIP (15), and that in CTD-IP varied from 33% to 100%
(6, 7, 15).
The poor prognosis of IP associated with RA have been reported
(22). Similar to the previous studies (6, 7, 15),RA was the most
common underlying disease which developed AE in this study
(Table 3). AE also developed in SS-IP and SLE-IP. Parambil et al.
(23) reported that three patients developed AE to die, among 18
patients with SS-IP (16.6%). And Lian et al. (24) reviewed 4038 SLE
patients and described that 9.4% of SLE patients associated IP and
1.1% of SLE-IP developed AE. This shows that AE may develop in
also SS-IP or SLE-IP. The prognosis and response to corticoster-
oid is different between the underlying CTDs. Especially, a rapid
progressive IP accompanied with PM/DM is corticosteroid resis-
tant and very poor prognosis (25). The survival rate of AE in this
study was 90%, which was better output among those studies. The
precise reasons of better outcome are not clear. However, the rate
of underlying CTDs such as RA and PM/DMmight affect the prog-
nosis of patients with AE in those reports. In addition, as an initial
characteristics of the study population, immunosuppressant was
used in 22% of patients in Suda’s study(7), in 80% of patients in
Tachikawa’s study (15), and the combination therapy of PSL and
other drug (immunosuppressant et al.) was used in 60% of patients
in this study (Table 1). The survival rate of each study was 17%,
67%, and 90% respectively (Table 3). This suggests that the use of
immunosuppressant just before AE may relate to good prognosis
during the clinical course after AE.
For the treatment of AE-IPF, high dose corticosteroid is usually
indicated according to the international guidelines and based on
expert opinion (weak positive recommendation), while there is no
recommendation regarding type, dose and duration of corticoster-
oids (14). Immunosuppressant can be combined with corticoster-
oid, yet without clear evidence of efficacy. Immunosuppressant
indicated for the treatment of AE-IPF generally consists in IVCY
(26), CsA or TAC. Some studies have shown that CsA and TAC
improved the outcome of AE-IPF and that they prevented the re-
lapse of AE (27-30). The AE of CTD-IP is managed according to
the AE-IPF, with high-dose corticosteroid and immunosuppressant.
The additional use of immunosuppressant with corticosteroid is
thought to be effective for AE and to decrease adverse effects of
corticosteroid. But, even though a few cases in this study, the pa-
tients with good response to corticosteroid significantly survived.
These results suggest that there are some cases in CTD-IP, show-
ing the good response to corticosteroid even when AE was compli-
cated. Taken together with our observations and the clinical course
of the previous studies (7, 27, 30), the prognosis of patients with
AE-IP who did not respond well to corticosteroid is extremely
poor, suggesting the significance of corticosteroid therapy in acute
phase of AE. Otherwise, if a drug- induced pneumonia causes a
respiratory deterioration, the prognosis may be good, and its dif-
ferential diagnosis is difficult.
Several limitations in the present study should be noted. First,
this was a retrospective study with small number of CTD-IP pa-
tients experienced AE. Therefore, there is a possibility that our
findings may not be clinically relevant. While, the additional use
of immunosuppressant revealed to be a significant poor prognostic
factor in this study, there is a possibility that only the patients in
inherently worse condition happened to be added immunosup-
pressant. Moreover, important parameters could have been missed
in this analysis. Second, this study was conducted in a single
institution, which could limit the generalizability of the findings.
Table 3. The incidence of CTD in AE of CTD-IP patients and outcome
Study (ref) No. of
CTD-IP
No. of
AE (%)
No. of patients
(No. of survivors from AE)
Survival
(%)
RA PM/DM SLE SS SSc
Park et al. (6) 93 4 (4.3) 3 (0) 0 0 0 1 (0) 0
Suda et al. (7) 83 6 (7.2) 5 (1) 0 0 1 (0) 0 17
Tachikawa et al. (15) ND 15 6 (5) 6 (3) 0 0 3 (2) 67a
Toyoda (this study) 155 10 (6.5) 6 (5) 2 (2) 1 (1) 1 (1) 0 90
ND ; no data, CTD ; connective tissue disease, AE ; acute exacerbation, CTD-IP ; connective tissue disease associated interstitial pneumonia, RA ;
rheumatoid arthritis, PM ; polymyositis, DM ; dermatomyositis, SLE ; systemic lupus erythematosus, SS ; Sjögren syndrome, SSc ; Systemic scle-
rosis
a ; The rate of 90 -day survived patients
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Further research on this topic should be performed involving
multiple medical institutions. Despite these limitations, the present
study provided useful information regarding the clinical features
and outcome of AE of CTD-IP.
In conclusion, the incidence of AE in CTD-IP in this study was
6.5%, which was comparable with previous findings, but the mortal-
ity was 10%, which was relatively better. The treatment with im-
munosuppressant for CTD and CTD-IP before AE onset might
improve the prognosis of AE of CTD-IP. Meanwhile, only the
additional use of immunosuppressant revealed to be a significant
poor prognostic factor, indicating the significance of corticosteroid
therapy in acute phase of AE.
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